Javascript must be enabled to continue!
WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
View through CrossRef
Genotoxic stress triggers a combined action of DNA repair and cell cycle checkpoint pathways. Protein phosphatase 2C delta (referred to as WIP1) is involved in timely inactivation of DNA damage response by suppressing function of p53 and other targets at chromatin. Here we show that WIP1 promotes DNA repair through homologous recombination. Loss or inhibition of WIP1 delayed disappearance of the ionizing radiation-induced 53BP1 foci in S/G2 cells and promoted cell death. We identify breast cancer associated protein 1 (BRCA1) as interactor and substrate of WIP1 and demonstrate that WIP1 activity is needed for correct dynamics of BRCA1 recruitment to chromatin flanking the DNA lesion. In addition, WIP1 dephosphorylates 53BP1 at Threonine 543 that was previously implicated in mediating interaction with RIF1. Finally, we report that inhibition of WIP1 allowed accumulation of DNA damage in S/G2 cells and increased sensitivity of cancer cells to a poly-(ADP-ribose) polymerase inhibitor olaparib. We propose that inhibition of WIP1 may increase sensitivity of BRCA1-proficient cancer cells to olaparib.
Title: WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
Description:
Genotoxic stress triggers a combined action of DNA repair and cell cycle checkpoint pathways.
Protein phosphatase 2C delta (referred to as WIP1) is involved in timely inactivation of DNA damage response by suppressing function of p53 and other targets at chromatin.
Here we show that WIP1 promotes DNA repair through homologous recombination.
Loss or inhibition of WIP1 delayed disappearance of the ionizing radiation-induced 53BP1 foci in S/G2 cells and promoted cell death.
We identify breast cancer associated protein 1 (BRCA1) as interactor and substrate of WIP1 and demonstrate that WIP1 activity is needed for correct dynamics of BRCA1 recruitment to chromatin flanking the DNA lesion.
In addition, WIP1 dephosphorylates 53BP1 at Threonine 543 that was previously implicated in mediating interaction with RIF1.
Finally, we report that inhibition of WIP1 allowed accumulation of DNA damage in S/G2 cells and increased sensitivity of cancer cells to a poly-(ADP-ribose) polymerase inhibitor olaparib.
We propose that inhibition of WIP1 may increase sensitivity of BRCA1-proficient cancer cells to olaparib.
Related Results
Abstract 1568: Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through upregulation of Wip1
Abstract 1568: Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through upregulation of Wip1
Abstract
(a)Metastasis is the leading cause of cancer-related deaths. Increasing evidence shows that cancer cells can disseminate from early primary lesions that are...
Abstract 1718: Schlafen 11 (SLFN11) is a critical determinant of cellular sensitivity to PARP inhibitors
Abstract 1718: Schlafen 11 (SLFN11) is a critical determinant of cellular sensitivity to PARP inhibitors
Abstract
Poly(ADP-ribose)polymerases (PARP) are DNA damage sensors and major repair factors for DNA single-strand breaks. Since the discovery of the synthetic lethal...
Abstract PR-10: PARP inhibition induces genomic instability in normal human cells.
Abstract PR-10: PARP inhibition induces genomic instability in normal human cells.
Abstract
Recent research has focused on poly(ADP-ribose) polymerases (PARPs) as potential chemotherapeutic targets. Tumors which harbor defects in DNA double-strand ...
Homologous Recombination—Experimental Systems, Analysis, and Significance
Homologous Recombination—Experimental Systems, Analysis, and Significance
Homologous recombination is the most complex of all recombination events that shape genomes and produce material for evolution. Homologous recombination events are exchanges betwee...
Abstract 363: CYT01B, a novel RAD51 inhibitor, acts synergistically with PARP inhibitors
Abstract 363: CYT01B, a novel RAD51 inhibitor, acts synergistically with PARP inhibitors
Abstract
Genomic instability is recognized as a driver of tumorigenesis and cancer progression. Loss of tumor suppressors or activation of oncogenes can induce DN...
Abstract B063: Interplay between PARP and the RB/E2F axis in prostate cancer
Abstract B063: Interplay between PARP and the RB/E2F axis in prostate cancer
Abstract
Retinoblastoma (RB) protein is a tumor suppressor that represses the transcriptional activity of E2Fs by forming an RB-E2F repressor complex. The phosphoryl...
PARP inhibitors in melanoma treatment: potential, challenges, and future directions
PARP inhibitors in melanoma treatment: potential, challenges, and future directions
Genome integrity is a critical driver of cellular stability, and defects in the processes that maintain genome health are potent sources of cancer progression. Homologous recombina...
PARP Inhibition as a Treatment Modality in Melanoma: What We Have Learned and What We Hope to Achieve
PARP Inhibition as a Treatment Modality in Melanoma: What We Have Learned and What We Hope to Achieve
Genome integrity is a critical driver of cellular stability, and defects in the processes that maintain genome health are potent sources of cancer progression. Homologous recombina...

